HALO logo
halo search icon
Arch Biopartners, Inc.

CA$0.44

Price Change Indicator
0.00 (0.00%)
Arch Biopartners, Inc.
ARCH · TSX

Arch Biopartners, Inc.

Start Trading ARCH for Free

CA$0.44

0.00 (0.00%)
19/05/2026 12:00:00 AM
All-CompaniesHALO All
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Arch Biopartners, Inc. Overview

ARCH Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About ARCH

icon

Website

Arch Biopartners, Inc.

icon

Telephone

1.647.428.7031

icon

Address

545 King Street West, Toronto, ON M5V 1M1

Description

Arch Biopartners, Inc. is a therapeutic biotech company developing novel, on-target drugs for kidney injury and disease. Its portfolio includes programs in both acute kidney injury (AKI) and chronic kidney disease (CKD), two serious conditions that affect hundreds of millions of patients worldwide. Arch's drug candidates, LSALT peptide and Cilastatin, are in Phase II clinical trials and have the potential to significantly improve outcomes for patients at risk of AKI. The company is also advancing its pre-clinical CKD platform targeting IL-32, a non-classical cytokine directly implicated in diabetic kidney disease, the main cause of kidney failure worldwide. The company was founded by Richard Gabriel Muruve and Daniel Muruve on March 4, 1983 and is headquartered in Toronto, Canada.

ARCH Price Chart

Key Stats

Market Cap

CA$29.89M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.39 - 1.95

Trade Value (12mth)

US$10,839.00

1 week

3.49%

1 month

-3.26%

YTD

-64.4%

1 year

-73.98%

All time high

5.30

Key Fundamentals

EPS 3 yr Growth

4.90%

EBITDA Margin

0.00%

Operating Cashflow

-$2m

Free Cash Flow Return

0.00%

ROIC

0.00%

Interest Coverage

-5.90

Quick Ratio

0.00

Other Data

Shares Outstanding (Fully Diluted)

66m

HALO Sector

Healthcare

Next Company Report Date

02-Feb-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

CAD

Short Sell (% of issue)

0.00

ARCH Fundamentals

Per Share Records

Historical data

Forecast data

CAD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
 $locklocklocklock-0.05-0.06-0.02locklocklock
EPS (Fully Diluted)
 $locklocklocklock-0.05-0.06-0.02locklocklock
Growth
 %locklocklocklock-135.8-15.961.7locklocklock
PE
 XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
 XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Arch Biopartners, Inc. (ARCH:TSX)?
Halo FAQ
The current share price of Arch Biopartners, Inc. (ARCH:TSX) is CAD$0.44.
What is the 52-week high share price for Arch Biopartners, Inc. (ARCH:TSX)?
Halo FAQ
The 52-week high share price for Arch Biopartners, Inc. (ARCH:TSX) is CAD$1.95.
What is the 52-week low share price for Arch Biopartners, Inc. (ARCH:TSX)?
Halo FAQ
The 52-week low share price for Arch Biopartners, Inc. (ARCH:TSX) is CAD$0.39.
What is the dividend yield for Arch Biopartners, Inc. (ARCH:TSX)?
Halo FAQ
Arch Biopartners, Inc. (ARCH:TSX) does not pay a dividend.
What was Arch Biopartners, Inc. (ARCH:TSX) last dividend payment?
Halo FAQ
Arch Biopartners, Inc. (ARCH:TSX) does not pay a dividend.
What is the franking level for Arch Biopartners, Inc. (ARCH:TSX)?
Halo FAQ
Arch Biopartners, Inc. (ARCH:TSX) has a franking level of 0.00%.
In which sector is Arch Biopartners, Inc. (ARCH:TSX) classified?
Halo FAQ
Arch Biopartners, Inc. (ARCH:TSX) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.
Start FREE Trial